Interferon alfacon-1

Phase 3Completed

4 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Hepatitis C

Conditions

Hepatitis C

Trial Timeline

— → —

NCT ID

NCT00239252

About Interferon alfacon-1

Interferon alfacon-1 is a phase 3 stage product being developed by Astellas Pharma for Hepatitis C. The current trial status is completed. This product is registered under clinical trial identifier NCT00239252. Target conditions include Hepatitis C.

What happened to similar drugs?

20 of 20 similar drugs in Hepatitis C were approved

Approved (20) Terminated (8) Active (0)

✅Pegasys® + Pegasys®Chugai PharmaceuticalApproved

✅Pegylated Interferon + RibavirinAstellas PharmaApproved

✅Glecaprevir-pibrentasvirAbbVieApproved

✅ABT450r-ABT267-ABT333 +/- RibavirinAbbVieApproved

✅PTV/r/OBV/DSVAbbVieApproved

✅SOF/LDV (sofosbuvir/ledipasvir) + PrOD (ombitasvir/paritaprevir/ritonavir with dasabuvir) (Phase 1 only) + EBR/GZR (elbasvir/grazoprevir) + RibavirinAbbVieApproved

✅OBV/PTV/r and DSV + Placebo to match OBV/PTV/r and DSVAbbVieApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00239252	Phase 3	Completed	—	—	Hepatitis C

Competing Products

20 competing products in Hepatitis C

See all competitors

Product	Company	Stage	Hype Score
VK2809 + Placebos	Viking Therapeutics	Phase 2	32
TERN-501 + TERN-101	Terns Pharmaceuticals	Phase 2	32
TERN-101	Terns Pharmaceuticals	Phase 2	32
TERN-201	Terns Pharmaceuticals	Phase 1	26
IVA337 + IVA337 + Placebo	Inventiva	Phase 2	29
IVA337 + Placebo + Empagliflozin	Inventiva	Phase 2	29
IVA337 + Placebo	Inventiva	Phase 3	41
Pegasys® + Pegasys®	Chugai Pharmaceutical	Approved	43
peginterferon alfa-2a + rivavirin	Chugai Pharmaceutical	Phase 3	40
SOF + COPE	Chugai Pharmaceutical	Pre-clinical	26
Colesevelam Hcl	Daiichi Sankyo	Phase 2	35
ASP9831 + Placebo	Astellas Pharma	Phase 2	35
FK788	Astellas Pharma	Phase 2	35
MK-2248	Merck	Phase 1	29
Pegylated Interferon + Ribavirin	Astellas Pharma	Approved	35
Tacrolimus + steroids, monoclonal anti-IL2R antibody	Astellas Pharma	Phase 2	35
Dolutegravir + Rlipivirine + GSK1265744	Shionogi	Phase 1	29
Dolutegravir + Methadone	Shionogi	Phase 1	29
Clevudine + Adefovir	Eisai	Phase 3	40
KRN7000	Kyowa Kirin	Phase 1/2	32